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Abstract
Peptidoglycan encases the bacterial cytoplasmic membrane to protect the cell from lysis due to the 
turgor. The final steps of peptidoglycan synthesis require a membrane-anchored substrate called 
lipid II, in which the peptidoglycan subunit is linked to the carrier lipid undecaprenol via a 
pyrophosphate moiety. Lipid II is the target of glycopeptide antibiotics and several antimicrobial 
peptides, and is degraded by ‘attacking’ enzymes involved in bacterial competition to induce lysis. 
Here we describe two protocols using thin-layer chromatography (TLC) and high pressure liquid 
chromatography (HPLC), respectively, to assay the digestion of lipid II by phosphatases such as 
Colicin M or the LXG toxin protein TelC from Streptococcus intermedius. The TLC method can 
also monitor the digestion of undecaprenyl (pyro)phosphate, whereas the HPLC method allows to 
separate the di-, mono- or unphosphorylated disaccharide pentapeptide products of lipid II.
Keywords
Lipid II; Undecaprenyl pyrophosphate; Phosphatase activity; Peptidoglycan; HPLC; TLC
Background
The peptidoglycan (PG) sacculus is an essential bacterial macromolecule that protects the 
cell from bursting due to its turgor and maintains the shape of the cell (Vollmer and 
Bertsche, 2008; Typas et al., 2012). PG is composed by glycan chains connected by short 
peptides. The PG from different species varies in the structure of the peptides and presence 
of secondary modifications (Vollmer et al., 2008). PG precursors are synthesized inside the 
cell and equipped with a carrier lipid for transport across the membrane prior to their 
polymerization at the outer leaflet of the cytoplasmic membrane (Barreteau et al., 2008). The 
universal bacterial carrier lipid is undecaprenyl phosphate (C55-P), which is synthesized in 
two steps. First, UppS uses farnesyl pyrophosphate (C15-PP) and eight isopentenyl 
pyrophosphate (C5-PP) molecules to produce the diphosphate form of the carrier lipid (C55-
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PP), which is then dephosphorylated to C55-P by membrane embedded phosphatases (UppP, 
or PAP2-type phosphatases) (Manat et al., 2014).
The final precursor for PG synthesis is lipid II, the GlcNAc-MurNAc(pentapepide) building 
block linked to C55-PP. Lipid II is synthesized in two steps at the inner leaflet of the 
cytoplasmic membrane from UDP-MurNAc-pentapeptide, UDP-GlcNAc and C55-P by the 
enzymes MraY and MurG (Bouhss et al., 2008). PG glycosyltransferases (GTases) 
polymerize lipid II at the outer leaflet of the membrane to glycan chains. This reaction 
releases C55-PP which is dephosphorylated for new rounds of precursor synthesis and 
transport.
Peptidoglycan synthesis is a prime target for antibacterial compounds and enzymes. Bacteria 
and higher organisms often produce antibacterial compounds to target competing bacteria 
and invading pathogens, respectively (Malanovic and Lohner, 2016). Bacterial competition 
is particularly fierce in dense populations such as biofilms and soil communities. Whilst the 
group of actinomycetes are known for their capability to secrete a repertoire of small 
metabolites that often show antibacterial activity, many Gram-negative bacteria utilize 
sophisticated type VI secretion systems to target adjacent bacterial cells by antimicrobial 
enzymes (Russell et al., 2011; 2012 and 2014). Another type of bacterial toxins are colicins, 
which are secreted by certain strains of Escherichia coli (Cascales et al., 2007). Colicins use 
energized nutrient uptake systems to enter the periplasm of susceptible strains of E. coli. 
Most colicins kill the target cell by inserting into the cytoplasmic membrane to form pores 
(Braun and Patzer, 2013). An exception is colicin M, which has a phosphatase activity 
against lipid II, cleaving the essential peptidoglycan precursor to disaccharide 
pyrophosphate and undecaprenol (El Ghachi et al., 2006).
More recently, it was shown that some Gram-positive species use a type VII secretion 
system to target other bacteria (Cao et al., 2016). So far the best example is Streptococcus 
intermedius, which uses a type VII secretion system to deliver an antibacterial toxin, TelC, 
to target bacteria (Whitney et al., 2017). TelC was shown to degrade lipid II and C55-PP to 
release disaccharide pentapeptide and pyrophosphate, respectively, and undecaprenol. S. 
intermedius also produces the immunity protein TipC, which inactivates TelC by direct 
interaction to prevent the lysis of the toxin-producing cell (Whitney et al., 2017). In this 
methods paper, we provide a detailed description of the TLC and HPLC methods that 
established the degradation of lipid II and C55-PP by TelC (Whitney et al., 2017). These 
methods can be generally used to assess the activity and specificity of phosphatases against 
membrane-bound bacterial cell wall precursors.
Materials and Reagents
1. Pipette tips (STARLAB, catalog numbers: S1111-3700, S1113-1700, 
S1111-6701)
2. 1.5 ml micro-tubes (SARSTEDT, catalog number: 72.690.001)
3. Aluminium HPTLC silica gel 60 plates, 20 x 20 cm, without fluorescent 
indicator (Merck, catalog number: 1.05547.0001)
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4. Glass vials (Soda glass, w/o rim, round bottom, 40 x 8 x 0.8-1.0 mm) (VWR, 
catalog number: 212-0011)
5. pH indicator strips (Merck, catalog number: 1.09531.0001)
6. HPLC vials (Agilent Technologies, catalog number: 5182-0553)
7. Vial inserts, 400 μl, glass, flat bottom (Agilent Technologies, catalog number: 
5181-3377)
8. Hypodermic needles (FINE-JECT® for single use) (VWR, catalog number: 
613-2022)
9. 2 ml micro-tubes (SARSTEDT, catalog number: 72.695.500)
10. MF-Millipore membrane filter 0.22 μm, mixed cellulose esters (Merck, catalog 
number: GSWP04700)
11. Enzyme of interest/putative phosphatase
12. Potassium chloride (KCl) (Analytical Reagent Grade) (Fisher Scientific, CAS 
number: 7447-40-7)
13. Triton X-100 (Roche Diagnostics, catalog number: 10789704001)
14. Lipid II (Lys version) (gift from Eefjan Breukink, University of Utrecht) (Egan et 
al., 2015)
Note: Lipid II can be produced and purified by previously reported methods 
(Brötz et al., 1995; Qiao et al., 2017).
15. Scintillation cocktail ProFlow G+ (Meridian Biotechnologies, catalog number: 
ProFlow G+)
Note: Used together with the radioactivity flow-through detector.
16. Calcium chloride anhydrous (CaCl2) (Melford Laboratories, catalog number: 
C1103)
17. Undecaprenyl monophosphate diammonium salt (Larodan, catalog number: 
62-1055)
18. Magnesium chloride hexahydrate (MgCl2·6H2O) (VWR, catalog number: 
25108.260)
19. Farnesyl pyrophosphate ammonium salt (Sigma-Aldrich, catalog number: 
F6892)
20. Isopentenyl pyrophosphate triammonium salt solution (Sigma-Aldrich, catalog 
number: I0503)
21. Undecaprenyl pyrophosphate synthase (UppS) from E. coli, purified as described 
in Pan et al., 2000
22. Undecaprenol (Larodan, catalog number: 60-1055)
23. n-Butanol (Honeywell International, catalog number: 537993)
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24. Pyridine, anhydrous 99.8% (Sigma-Aldrich, catalog number: 270970)
25. Iodine (Sigma-Aldrich, catalog number: I3380)
26. [14C]GlcNAc-labeled lipid II (Lys version) (gift from Eefjan Breukink, 
University of Utrecht) (Egan et al., 2015)
27. Chloroform (Sigma-Aldrich, catalog number: 32211-M)
28. Methanol (Fisher Scientific, catalog number: 10284580)
29. Sodium chloride (NaCl) (VWR, catalog number: 27810.295)
30. Methanol (CHROMASOLV™, gradient grade, for HPLC, ≥ 99.9%) (Honeywell 
International, Riedel-de Haën™, catalog number: 34885)
31. Peptidoglycan synthase PBP1B and its cognate activator LpoB proteins from E. 
coli, purified as described in Bertsche et al. (2006) and Egan et al. (2014)
32. Sodium borohydride (Merck, catalog number: 1.06371.0100)
33. Milli Q quality water (ddH2O)
34. Ammonium hydroxide (Honeywell International, catalog number: 05003)
35. Acetic acid > 99.8% (Sigma-Aldrich, catalog number: 33209-M)
36. 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (VWR, catalog 
number: 441485H)
37. Potassium hydroxide (KOH) (Sigma-Aldrich, catalog number: P5958-500G)
38. Sodium hydroxide (NaOH) (VWR, catalog number: 28245.298)
39. Sodium hydroxide for HPLC (semiconductor grade, 99.99% trace metals basis) 
(Sigma-Aldrich, catalog number: 306576)
40. ortho-Phosphoric acid, 85-90% (HPLC) (Honeywell International, Fluka™, 
catalog number: 79606)
41. Boric acid (99.97% trace metals basis) (Sigma-Aldrich, catalog number: 339067)
42. Muramidase cellosyl (provided by Höchst AG, Frankfurt, Germany)
Note: Alternatively, the muramidase mutanolysin (Sigma-Aldrich, catalog 
number: M9901) can be used.
43. Sodium azide (NaN3) (Sigma-Aldrich, catalog number: S2002)
44. Mobile phase (see Recipes)
45. Undecaprenol and undecaprenyl monophosphate diammonium salt (see Recipes)
46. 6 M pyridinium acetate (see Recipes)
47. n-Butanol/pyridinium acetate pH 4.2 (see Recipes)
48. HEPES/KOH stock solution (1 M, pH 7.5) (see Recipes)
49. HEPES/NaOH stock solution (1 M, pH 7.5) (see Recipes)
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50. Sodium phosphate buffer (80 mM, pH 4.8) (see Recipes)
51. Muramidase cellosyl (0.5 μg μl-1) (see Recipes)
52. Sodium borate (0.5 M, pH 9.0) (see Recipes)
53. HPLC buffer A (see Recipes)
54. HPLC buffer B (see Recipes)
Equipment
1. Pipettes (Gilson, catalog numbers: F167300 and F167500)
2. AccuTherm Microtube Shaking Incubator (Labnet International, model: 
AccuTherm™, catalog number: I-4002-HCS)
3. Vacuum concentration system (Labogene, model: MaxiVac Alpha)
4. Bench top centrifuge, for example Accuspin Micro 17 microcentrifuge (Fisher 
Scientific, model: accuSpin™ Micro 17, catalog number: 75002460)
5. Chemical fume hood
6. TLC developing chamber (VWR, catalog number: 552-0363)
7. Proheat® heat gun (Sigma-Aldrich, catalog number: Z673722-1EA)
8. Small beaker (Petri dish, Steriplan®) (VWR, catalog number: 391-2840)
9. Dry bath (Digital Dry Bath, Labnet International, catalog number: D1100-230V)
10. HPLC apparatus (Agilent Technologies, model: 1200 Series) with flow detector 
for radioactivity (LabLogic Systems, model: Beta-RAM 5)
11. ProntoSIL 120-3-C18AQ3um 250 x 4.6 mm HPLC column (Bischoff 
Chromatography, catalog number: 2546F184PS030)
12. IKA RH basic 2 magnetic stirrer (IKA, catalog number: 0003339002)
13. Vortex (IKA, model: Minishaker MS2)
14. pH meter (Cole-Parmer, Jenway, model: 3510, catalog number: 351001)
15. Incubator (Genlab, catalog number: INC/100/DIG)
16. Brown glass vials (Fisher Scientific, catalog number: 11531474)
Part I: Thin-layer chromatography assay
Procedure
A. Enzymatic digestion of lipid II or undecaprenyl pyrophosphate
Note: All reactions are carried out in 1.5 ml microtubes and incubated using a 
microtube shaking incubator at 800 rpm.
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1. Reactions are carried out in a final volume of 50 μl and set up as 
described below for each substrate. All enzyme substrates are dried 
under vacuum and subsequently solubilized in the reaction mixture.
Note: Take into account the constituents present in the storage buffer of 
the assayed proteins to calculate the buffer mixture.
a. Lys-type lipid II
Prepare enzyme reactions with final concentrations of 30 mM 
HEPES/KOH pH 7.5, 150 mM KCl, 0.1% (w/v) Triton X-100, 
40 µM lipid II (L-Lys). Add 2 µM phosphatase (e.g., TelCt), 
phosphatase-inhibitor complex (e.g., TelCt-TipC complex) or 
no enzyme (control) and incubate for 90 min at 37 °C.
b. Undecaprenyl monophosphate
Prepare enzyme reactions with final concentrations of 20 mM 
HEPES/KOH pH 7.5, 150 mM KCl, 1 mM CaCl2, 0.1% (w/v) 
Triton X-100, 100 µM undecaprenyl monophosphate. Add 2 
µM phosphatase (e.g., TelCt) or no enzyme (control) and 
incubate for 90 min at 37 °C.
c. Undecaprenyl pyrophosphate synthesis coupled to the 
degradation by TelCt
Prepare enzyme reactions with final concentrations of 20 mM 
HEPES/KOH pH 7.5, 50 mM KCl, 0.5 mM MgCl2, 1 mM 
CaCl2, 0.1% (w/v) Triton X-100, 40 µM farnesyl 
pyrophosphate, 400 µM isopentenyl pyrophosphate, 10 µM 
UppS. Add 2 µM phosphatase (e.g., TelCt), phosphatase-
inhibitor complex (e.g., TelCt-TipC complex) or no enzyme 
(control) and incubate for 5 h at 25 °C, followed by an 
additional incubation for 90 min at 37 °C.
d. Undecaprenol
Prepare enzyme reactions with final concentrations of 30 mM 
HEPES/KOH pH 7.5, 150 mM KCl, 0.1% (w/v) Triton X-100 
and 100 µM undecaprenol. Incubate for 90 min at 37 °C.
2. Terminate the reactions by adding 50 µl of n-butanol/pyridine acetate 
(2:1) pH 4.2.
3. Vortex for 1 min and centrifuge for 3 min at 17,000 x g using a bench-
top centrifuge to separate the organic phase (n-butanol) from the 
aqueous phase (pyridine-acetate, water).
Note: This step is essential to extract hydrophobic (lipid II, C55-P, C55-
OH) and amphiphilic (C55-PP and Triton X-100) substances from the 
mixture. These substances will be found in the upper, organic phase 
which will contribute to 1/3 of the total volume.
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B. Thin layer chromatography
Note: All steps are carried out in a chemical fume hood at room temperature if 
not indicated otherwise. The basic procedure for thin layer chromatography is 
shown in the published movie (Cockburn and Koropatkin, 2015).
1. Pour the mobile phase into the developing chamber and adjust the 
solvent level to 1 cm.
2. Close the chamber with the lid and allow for saturation of the gaseous 
phase with solvent (60 min).
3. Incubate the TLC plate for at least 1 h at 60 °C to remove any humidity 
left from storage.
4. Use a pencil to draw a line 1.5 cm from the bottom of the plate and 
mark sample spots. Sample spots are separated by 2 cm, and the 
distance from the outer spots to the edge of the plate should be at least 4 
cm.
5. Load the complete organic phase (upper phase, see Step A3) in 10 µl 
aliquots on the sample spots. After the addition of each aliquot, the spot 
is dried with a heat gun. Alternatively, the plate is left under a fume 
hood for each drying step.
Note: It is important that the lower (aqueous) phase is not transferred on 
the plate, as this will result in smearing of the spots. When using a heat 
gun, it is important to not overheat the spots, as this can lead to 
degradation of compounds and additional bands.
6. Place the TLC carefully in the developing chamber such that the solvent 
does not reach the spots. Optimally, there should be a distance of 0.5 
cm between the solvent level and the pencil line.
7. The TLC plate is incubated in the chamber with the lid on until the 
solvent front reaches 4/5 of the plate length, which takes 1.5-2 h.
C. Staining
1. Remove the plate from the chamber and dry it with a heat gun. The 
plate should be completely dried to avoid the appearance of solvent 
bands during staining.
2. Place a small beaker with iodine in the chamber and put the lid on. 
Saturation will take 20-30 min at room temperature.
3. Place the plate in the development chamber saturated with iodine vapor 
and incubate it until the spots are clearly visible (20 min-1 h).
4. Representative examples of each reaction are shown in Figure 1.
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Data analysis
Take a high-resolution picture and determine the retention factor (Rf) using commercially 
available programs (e.g., ImageJ). Bands present in control reactions serve as a standard.
R f =
distance of the substance zone from the sample origin [mm]
solvent front migration distance [mm]
Note: The distance is measured from the application line to the middle of the substance 
spots. For asymmetric spots (here: undecaprenyl pyrophosphate) measure the distance 
between the application line and lowest point of the spot. Spots in reaction mixtures should 
have similar Rf values, shape and color as spots derived from the standard compounds.
Part II: High performance liquid chromatography assay
Procedure
A. Lipid II reactions for HPLC assay
Note: A control reaction, containing the peptidoglycan synthase PBP1B and its 
cognate activator LpoB, is assayed to polymerize lipid II into short glycan chains 
with C55-PP at the terminal MurNAc residue.
1. Dry 10,000 dpm (~1 nmol) of [14C]GlcNAc-labeled lipid II-Lys, stored 
in chloroform/methanol (1:1), in a glass vial using a vacuum.
2. Resuspend the lipid II in 5 μl of 0.2% (w/v) Triton X-100 and vortex for 
10 sec at 1,800 rpm.
3. Prepare in a 1.5 ml microtube a reaction buffer mixture with final 
concentrations of 15 mM HEPES/NaOH, pH 7.5, 10 mM MgCl2, 150 
mM NaCl, 0.023% (w/v) Triton X-100 and 0.4 mM CaCl2 (the PBP1B-
LpoB control reaction did not contain CaCl2) in a total reaction volume 
of 100 μl.
Note: Take into account the constituents present in the storage buffer of 
the assayed proteins to calculate the buffer mixture.
4. Add 2 μM phosphatase (e.g., TelCt or Colicin M) or phosphatase-
inhibitor complex (TelCt-TipC) to the reaction buffer. For a control 
sample add 0.75 μM PBP1B and 1.5 μM LpoB to the reaction buffer.
5. Add the reaction mixture to the resuspended lipid II and incubate it for 
60 min in a microtube shaking incubator at 37 °C with shaking (800 
rpm).
6. Spin down the condensation using a microcentrifuge.
Reactions with phosphatases (TelCt, TelCt-TipC or Colicin M) are processed as 
follows:
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7. Adjust the pH of the sample to 3.5-4.0 using 20% phosphoric acid and pH 
indicator stripes.
Note: Measure the pH by putting 0.3 μl sample onto the pH indicator stripe.
8. Centrifuge the sample in a microcentrifuge for 15 min at maximum speed 
and room temperature. Transfer the supernatant into an HPLC vial 
containing a 400 µl vial insert.
The control reaction with PBP1B-LpoB requires additional steps to digest the 
peptidoglycan with a muramidase and reduce the resulting unphosphorylated 
muropeptides. After Step A6 the reaction must be processed as follows:
9. Incubate samples for 5 min at 100 °C using a dry bath, then spin down the 
condensation using a microcentrifuge.
10. Let the samples cool down at room temperature for 2 min.
11. Add 30 μl of cellosyl buffer (80 mM sodium phosphate, pH 4.8) and 10 
µl of 0.5 µg µl-1 cellosyl (or mutanolysin) to the sample.
12. Incubate the samples for 70 min in a microtube shaking incubator at 
37 °C with shaking (800 rpm).
13. Spin down the condensation using a microcentrifuge.
14. Boil the reaction for 10 min at 100 °C on a dry bath and centrifuge the 
sample using a microcentrifuge for 15 min at maximum speed and room 
temperature.
15. Punch a hole in the lid of a new 2 ml microcentrifuge tube using a 
needle.
Note: The hole will allow releasing the H2 gas produced during the 
reduction step.
16. Transfer the supernatant to the 2 ml microcentrifuge tube.
17. Reduce the muropeptides by adding 100 μl of 0.5 M sodium borate, pH 
9.0 and a tip of a spatula of solid sodium borohydride (ca. 1 mg).
18. Incubate the sample for 30 min at room temperature in a microcentrifuge 
at 4,700 x g to prevent spillage due to gas bubbles.
19. Adjust the pH of the sample to 3.5-4.0 using 20% phosphoric acid and 
pH indicator stripes.
Note: Measure the pH by putting 0.3 μl of sample onto the pH indicator 
stripe.
20. Centrifuge the sample in a microcentrifuge for 15 min at maximum 
speed and room temperature. Transfer the supernatant into an HPLC vial 
containing a 400 µl vial insert.
B. Detection of lipid II products by HPLC
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System and set up conditions:
HPLC connected to a radioactivity flow-through detector
C18 reversed-phase column
Flow rate: 0.5 ml min-1
Column temperature: 55 °C
1. Wash with 100% methanol for 20 min at room temperature.
2. Increase column temperature to 55 °C.
3. Start a linear gradient for 30 min from 100% methanol to 100% Milli Q 
water, holding 100% Milli Q water for further 20 min.
4. Wash with HPLC buffer B for 20 min and equilibrate the column with 
HPLC buffer A for 40 min.
5. Do a buffer run following the same method used for the samples of 
interest (Steps B6-B9) but without injecting any sample.
6. Inject the sample (leave 20 µl of the total reaction volume in the vial 
insert) and flush the injection loop with HPLC buffer A for 2 min.
7. Start a linear elution gradient for 60 min from 100% HPLC buffer A to 
50% HPLC buffer B, holding 50% HPLC buffer B for further 10 min.
8. Re-equilibrate the column with 100% HPLC buffer A for 30 min.
9. Inject the next sample.
Representative HPLC chromatograms of each sample are shown in Figure 2.
Data analysis
1. Each reaction should be assayed in triplicate.
2. The produced muropeptides are identified based on their retention time, using the 
software provided with the HPLC system (e.g., Laura™, LabLogic Systems Ltd).
3. If needed, the phosphatase product can be verified by mass spectrometry. For 
this, use 16 nmol of non-radioactive lipid II (Lys version) as substrate to perform 
the reaction as described above, using a UV detector set at 205 nm, and collect 
the product fraction. Dry the collected fraction in a SpeedVac and store it at 
-20 °C until mass spectrometry analysis as reported (Bui et al., 2009).
Note: The products can be collected either manually or using the HPLC collector 
module.
Recipes
Note: Unless otherwise indicated, all stock solutions are prepared using Milli Q water.
1. Mobile phase (according to Rick et al., 1998)
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Mix components in the following order under gentle stirring:
10 ml water
1 ml 36% ammonium hydroxide
48 ml methanol
88 ml chloroform
Store in a brown glass bottle
Note: Chloroform should be added step-wise and slowly to prevent phase 
separation.
2. Undecaprenol and undecaprenyl monophosphate diammonium salt
Prepare 1 mM solutions in chloroform-methanol (2:1, v:v)
Store in brown glass vials at -20 °C
3. 6 M pyridinium acetate
Mix 51.5 ml glacial acetic acid with 48.5 ml of pyridine
4. n-Butanol/pyridinium acetate pH 4.2 (according to van Heijenoort et al., 1992)
Mix 50 ml n-butanol with 25 ml 6 M pyridinium acetate
5. HEPES/KOH stock solution (1 M, pH 7.5)
Dissolve 23.83 g N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
(HEPES) in 90 ml of Milli Q water
Adjust pH to 7.5 with potassium hydroxide (1 M)
Adjust to a final volume of 100 ml
6. HEPES/NaOH stock solution (1 M, pH 7.5)
Dissolve 23.83 g N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
(HEPES) in 90 ml of Milli Q water
Adjust pH to 7.5 with sodium hydroxide (1 M)
Adjust to a final volume of 100 ml
7. Sodium phosphate buffer (80 mM, pH 4.8)
Dissolve 0.64 g sodium hydroxide (for HPLC) in 150 ml Milli Q water
Adjust pH to 4.8 with phosphoric acid (85% and 20%)
Adjust to a final volume of 200 ml
8. Muramidase cellosyl (0.5 μg μl-1)
Dissolve 5 mg of freeze-dried muramidase cellosyl stock in 10 ml of 20 mM 
sodium phosphate, pH 4.8
Aliquot in microtubes and store at -20 °C
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9. Sodium borate (0.5 M, pH 9.0)
Dissolve 3.09 g boric acid in 75 ml Milli Q water
Adjust pH to 9.0 with sodium hydroxide (10 M)
Adjust to a final volume of 100 ml
10. HPLC buffer A (50 mM sodium phosphate, pH 4.31 with 10 μl of 10% sodium 
azide per liter of buffer)
Dissolve 4 g sodium hydroxide (for HPLC) in 1,900 ml Milli Q water
Adjust pH to pH 4.31 with phosphoric acid (85% and 20%)
Adjust to a final volume of 2 L
Filter the buffer using a 0.22 μm filter
Add 20 μl of 10% sodium azide
11. HPLC buffer B (75 mM sodium phosphate, pH 4.95, 15% v/v methanol)
Dissolve 6 g sodium hydroxide (for HPLC) in 1,500 ml Milli Q water
Adjust pH to pH 4.95 with phosphoric acid (85% and 20%)
Adjust to a final volume of 1.7 L
Filter the buffer through a 0.22 μm filter
Add 300 ml of methanol for HPLC
Acknowledgments
This work reports in detail the methods previously used to demonstrate the cleavage site of TelC in peptidoglycan 
precursors (Whitney et al., 2017). This work was funded by the UK Medical Research Council (MRC) within the 
Joint Programming Initiative on Antimicrobial Resistance ANR-14-JAMR-0003 (NAPCLI) and the AMR Cross-
council initiative Collaborative Grant MR/N002679/1.
References
1. Barreteau H, Kovac A, Boniface A, Sova M, Gobec S, Blanot D. Cytoplasmic steps of 
peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008; 32(2):168–207. [PubMed: 18266853] 
2. Bertsche U, Kast T, Wolf B, Fraipont C, Aarsman ME, Kannenberg K, von Rechenberg M, Nguyen-
Disteche M, den Blaauwen T, Holtje JV, Vollmer W. Interaction between two murein 
(peptidoglycan) synthases, PBP3 and PBP1B, in Escherichia coli. Mol Microbiol. 2006; 61(3):675–
690. [PubMed: 16803586] 
3. Bouhss A, Trunkfield AE, Bugg TD, Mengin-Lecreulx D. The biosynthesis of peptidoglycan lipid-
linked intermediates. FEMS Microbiol Rev. 2008; 32(2):208–233. [PubMed: 18081839] 
4. Braun V, Patzer SI. Intercellular communication by related bacterial protein toxins: colicins, contact-
dependent inhibitors, and proteins exported by the type VI secretion system. FEMS Microbiol Lett. 
2013; 345(1):13–21. [PubMed: 23701660] 
5. Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG. Mode of action of the lantibiotic mersacidin: 
inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother. 
1995; 39(3):714–719. [PubMed: 7793878] 
Pazos et al. Page 12
Bio Protoc. Author manuscript; available in PMC 2018 April 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
6. Bui NK, Gray J, Schwarz H, Schumann P, Blanot D, Vollmer W. The peptidoglycan sacculus of 
Myxococcus xanthus has unusual structural features and is degraded during glycerol-induced 
myxospore development. J Bacteriol. 2009; 191(2):494–505. [PubMed: 18996994] 
7. Cao Z, Casabona MG, Kneuper H, Chalmers JD, Palmer T. The type VII secretion system of 
Staphylococcus aureus secretes a nuclease toxin that targets competitor bacteria. Nat Microbiol. 
2016; 2:16183. [PubMed: 27723728] 
8. Cascales E, Buchanan SK, Duche D, Kleanthous C, Lloubes R, Postle K, Riley M, Slatin S, Cavard 
D. Colicin biology. Microbiol Mol Biol Rev. 2007; 71(1):158–229. [PubMed: 17347522] 
9. Cockburn D, Koropatkin N. Product analysis of starch active enzymes by TLC. Bio-protocol. 2015; 
5(20):e1621.
10. Egan AJF, Biboy J, van’t Veer I, Breukink E, Vollmer W. Activities and regulation of 
peptidoglycan synthases. Phil Trans R Soc B. 2015; 370 20150031. 
11. Egan AJ, Jean NL, Koumoutsi A, Bougault CM, Biboy J, Sassine J, Solovyova AS, Breukink E, 
Typas A, Vollmer W, Simorre JP. Outer-membrane lipoprotein LpoB spans the periplasm to 
stimulate the peptidoglycan synthase PBP1B. PNAS. 2014; 111(22):8197–8202. [PubMed: 
24821816] 
12. El Ghachi M, Bouhss A, Barreteau H, Touze T, Auger G, Blanot D, Mengin-Lecreulx D. Colicin M 
exerts its bacteriolytic effect via enzymatic degradation of undecaprenyl phosphate-linked 
peptidoglycan precursors. J Biol Chem. 2006; 281(32):22761–22772. [PubMed: 16777846] 
13. Malanovic N, Lohner K. Antimicrobial peptides targeting gram-positive bacteria. Pharmaceuticals 
(Basel). 2016; 9(3)
14. Manat G, Roure S, Auger R, Bouhss A, Barreteau H, Mengin-Lecreulx D, Touze T. Deciphering 
the metabolism of undecaprenyl-phosphate: the bacterial cell-wall unit carrier at the membrane 
frontier. Microb Drug Resist. 2014; 20(3):199–214. [PubMed: 24799078] 
15. Pan JJ, Chiou ST, Liang PH. Product distribution and pre-steady-state kinetic analysis of 
Escherichia coli undecaprenyl pyrophosphate synthase reaction. Biochemistry. 2000; 39(35):
10936–10942. [PubMed: 10978182] 
16. Qiao Y, Srisuknimit V, Rubino F, Schaefer K, Ruiz N, Walker S, Kahne D. Lipid II overproduction 
allows direct assay of transpeptidase inhibition by β-lactams. Nat Chem Biol. 2017; 13(7):793–
798. [PubMed: 28553948] 
17. Rick PD, Hubbard GL, Kitaoka M, Nagaki H, Kinoshita T, Dowd S, Simplaceanu V, Ho C. 
Characterization of the lipid-carrier involved in the synthesis of enterobacterial common antigen 
(ECA) and identification of a novel phosphoglyceride in a mutant of Salmonella typhimurium 
defective in ECA synthesis. Glycobiology. 1998; 8(6):557–567. [PubMed: 9592122] 
18. Russell AB, Hood RD, Bui NK, LeRoux M, Vollmer W, Mougous JD. Type VI secretion delivers 
bacteriolytic effectors to target cells. Nature. 2011; 475(7356):343–347. [PubMed: 21776080] 
19. Russell AB, Peterson SB, Mougous JD. Type VI secretion system effectors: poisons with a 
purpose. Nat Rev Microbiol. 2014; 12(2):137–148. [PubMed: 24384601] 
20. Russell AB, Singh P, Brittnacher M, Bui NK, Hood RD, Carl MA, Agnello DM, Schwarz S, 
Goodlett DR, Vollmer W, Mougous JD. A widespread bacterial type VI secretion effector 
superfamily identified using a heuristic approach. Cell Host Microbe. 2012; 11(5):538–549. 
[PubMed: 22607806] 
21. Typas A, Banzhaf M, Gross CA, Vollmer W. From the regulation of peptidoglycan synthesis to 
bacterial growth and morphology. Nat Rev Microbiol. 2012; 10(2):123–136.
22. van Heijenoort Y, Gomez M, Derrien M, Ayala J, van Heijenoort J. Membrane intermediates in the 
peptidoglycan metabolism of Escherichia coli: possible roles of PBP 1b and PBP 3. J Bacteriol. 
1992; 174(11):3549–3557. [PubMed: 1592809] 
23. Vollmer W, Bertsche U. Murein (peptidoglycan) structure, architecture and biosynthesis in 
Escherichia coli. Biochim Biophys Acta. 2008; 1778(9):1714–1734. [PubMed: 17658458] 
24. Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol 
Rev. 2008; 32(2):149–167. [PubMed: 18194336] 
25. Whitney JC, Peterson SB, Kim J, Pazos M, Verster AJ, Radey MC, Kulasekara HD, Ching MQ, 
Bullen NP, Bryant D, Goo YA, et al. A broadly distributed toxin family mediates contact-
Pazos et al. Page 13
Bio Protoc. Author manuscript; available in PMC 2018 April 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
dependent antagonism between gram-positive bacteria. Elife. 2017; 6:e26938. [PubMed: 
28696203] 
Pazos et al. Page 14
Bio Protoc. Author manuscript; available in PMC 2018 April 10.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 1. Lipid II and C55-PP, but not C55-P, are substrates of TelCt.
Thin-layer chromatography analysis of the products obtained in reactions of TelCt (toxin 
domain of TelC) or TelCt-TipC with (A) C55-P, (B) C55-PP or (C) lipid II. D. C55-OH 
migrates at the solvent front. Control samples (-) contained no protein. TelCt was active 
against lipid II and C55-PP and was inhibited by its immunity protein TipC. The figure was 
adopted from Whitney et al. (2017).
Note: Only lipid II and undecaprenyl monophosphate will appear as sharp bands. Due to its 
amphiphilic nature undecaprenyl pyrophosphate will appear as a crescent-shaped band 
between lipid II and undecaprenyl phosphate. The hydrophobic undecaprenol will always 
migrate at the solvent front, but will be visible after iodine staining.
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Figure 2. TelCt cleaves lipid II between undecaprenyl and pentapeptide-pyrophosphate.
A. HPLC chromatograms of the radiolabeled products resultant from reactions containing 
Lys-Lipid II and the indicated proteins. PBP1B + LpoB reaction was further digested with 
cellosyl and reduced with sodium borohydride. B. Proposed structures of the main products 
(peaks 1-3 in panel A) of each reaction. GlcNAc, N-acetylglucosamine; MurNAc-PP, N-
acetylmuramic acid pyrophosphate; MurNAc-P, N-acetylmuramic acid phosphate; 
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MurNAc(r), N-acetylmuramitol; L-Ala, L-alanine; L-Lys, L-lysine; D-iGlu, D-isoglutamic 
acid; D-Ala, D-alanine. The figure was adopted from Whitney et al. (2017).
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